Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | June 29, 2024 | July 01, 2024 |
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director | May 05, 2025 | May 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date June 29, 2024 · Filed July 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 27,302 |
Ending reported balance
After 2024-06-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-29 · Exercise / conversion · Acquired 6,104 · Balance 28,767 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2024-06-29 · Tax withholding · Disposed 1,465 · Balance 27,302 |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-06-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-29 · Exercise / conversion · Disposed 6,104 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: This award is fully vested in accordance with its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: This award is fully vested in accordance with its terms.
Amneal Pharmaceuticals, Inc.
Report date May 05, 2025 · Filed May 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 211,029 |
Reported balance
After 2025-05-05 transaction · row 1
1 source rowRow 1 · 2025-05-05 · Exercise / conversion · Acquired 40,258 · Balance 211,029 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-05 · Exercise / conversion · Disposed 40,258 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 34,819 |
Reported balance
After 2025-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-06 · Grant · Acquired 34,819 · Balance 34,819 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025.
F3: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2025 Filed May 8, 2025 18:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 34,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-023987 · wk-form4_1746744960.xml · derivative · entry 3 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,819 Underlying: Class A Common Stock · 34,819 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| May 05, 2025 Filed May 8, 2025 18:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 40,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-023987 · wk-form4_1746744960.xml · derivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 40,258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. F2 · derivative.expiration_date: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. Read SEC document |
| May 05, 2025 Filed May 8, 2025 18:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 40,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-023987 · wk-form4_1746744960.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:16 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 80,000 | $8.90 | $712,000.00 |
DisclosureSEC source: 0001628280-25-011300 · wk-form4_1741382194.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,771 F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.62 to $9.00 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 16:51 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019581 · form4.xml · derivative · entry 3 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 16:51 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,465 | $24.10 | $35,306.50 |
DisclosureSEC source: 0001127602-24-019581 · form4.xml · nonDerivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,302 Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 16:51 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019581 · form4.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 09, 2024 Filed Jun 10, 2024 20:56 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,871 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018322 · form4.xml · derivative · entry 3 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,871 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 09, 2024 Filed Jun 10, 2024 20:56 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 930 | $23.91 | $22,236.30 |
DisclosureSEC source: 0001127602-24-018322 · form4.xml · nonDerivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,663 Read SEC document |
| June 09, 2024 Filed Jun 10, 2024 20:56 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,871 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018322 · form4.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 16:45 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 17,492 | $0.00 Strike: $23.40 | $0.00 |
DisclosureSEC source: 0001127602-24-017710 · form4.xml · derivative · entry 9 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,492 Underlying: Ordinary Shares · 17,492 shares Expires 2034-05-31 F9 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/31/2025. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 16:45 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017710 · form4.xml · derivative · entry 8 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,013 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F8 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. F8 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. Read SEC document |
| May 10, 2024 Filed May 14, 2024 16:45 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 76,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-023262 · wk-form4_1715719548.xml · derivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 76,453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 9, 2023, the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024. F2 · derivative.expiration_date: On May 9, 2023, the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024. Read SEC document |
| May 10, 2024 Filed May 14, 2024 16:45 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 76,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023262 · wk-form4_1715719548.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 02, 2024 Filed May 6, 2024 17:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 40,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-020715 · wk-form4_1715030214.xml · derivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,258 Underlying: Class A Common Stock · 40,258 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 16:45 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-017710 · form4.xml · derivative · entry 7 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 119 shares Expires not disclosed F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 16:45 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 254 | $30.72 Strike: $30.72 | $7,802.88 |
DisclosureSEC source: 0001127602-24-017710 · form4.xml · derivative · entry 6 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,986 Underlying: Ordinary Shares · 254 shares Expires 2033-06-29 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F6 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 16:45 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 231 | $30.86 Strike: $30.86 | $7,128.66 |
DisclosureSEC source: 0001127602-24-017710 · form4.xml · derivative · entry 5 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,785 Underlying: Ordinary Shares · 231 shares Expires 2032-07-07 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 16:45 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 313 | $24.24 Strike: $24.24 | $7,587.12 |
DisclosureSEC source: 0001127602-24-017710 · form4.xml · derivative · entry 4 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,990 Underlying: Ordinary Shares · 313 shares Expires 2031-06-14 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 16:45 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 75 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-017710 · form4.xml · derivative · entry 3 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,871 Underlying: Ordinary Shares · 75 shares Expires not disclosed F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/9/2022. F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/9/2022. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 16:45 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 455 | $24.22 Strike: $24.22 | $11,020.10 |
DisclosureSEC source: 0001127602-24-017710 · form4.xml · derivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,214 Underlying: Ordinary Shares · 455 shares Expires 2031-06-09 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F3 · derivative.exercise_date: Shares subject to the stock option award vest in three equal annual installments commencing on 6/9/2022. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 16:45 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 22 | $24.22 Strike: $24.22 | $532.84 |
DisclosureSEC source: 0001127602-24-017710 · form4.xml · derivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,137 Underlying: Ordinary Shares · 22 shares Expires 2031-06-09 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| July 07, 2023 Filed Jul 10, 2023 20:26 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020544 · form4.xml · derivative · entry 3 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| July 07, 2023 Filed Jul 10, 2023 20:26 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,430 | $29.88 | $42,728.40 |
DisclosureSEC source: 0001127602-23-020544 · form4.xml · nonDerivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,722 Read SEC document |
| July 07, 2023 Filed Jul 10, 2023 20:26 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020544 · form4.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 16:30 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019622 · form4.xml · derivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,985 Underlying: Ordinary Shares · 5,985 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 16:30 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 12,732 | $0.00 Strike: $31.33 | $0.00 |
DisclosureSEC source: 0001127602-23-019622 · form4.xml · derivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,732 Underlying: Ordinary Shares · 12,732 shares Expires 2033-06-29 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 17:53 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018599 · form4.xml · derivative · entry 3 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,796 Underlying: Ordinary Shares · 3,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/9/2022. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/9/2022. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 17:53 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 911 | $31.13 | $28,359.43 |
DisclosureSEC source: 0001127602-23-018599 · form4.xml · nonDerivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,195 Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 17:53 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018599 · form4.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 10, 2023 Filed May 11, 2023 16:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 80,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028737 · doc4.xml · derivative · entry 3 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 80,128 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On May 9, 2022 the reporting person was granted 80,128 restricted stock units vesting on May 10, 2023. F3 · derivative.expiration_date: On May 9, 2022 the reporting person was granted 80,128 restricted stock units vesting on May 10, 2023. Read SEC document |
| May 10, 2023 Filed May 11, 2023 16:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 80,128 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028737 · doc4.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 09, 2023 Filed May 11, 2023 16:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 76,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028737 · doc4.xml · derivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,453 Underlying: Class A Common Stock · 76,453 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 16:17 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,554 | $0.00 Strike: $31.48 | $0.00 |
DisclosureSEC source: 0001127602-22-019125 · form4.xml · derivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,554 Underlying: Ordinary Shares · 11,554 shares Expires 2032-07-07 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 7/7/2023. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 16:17 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-019125 · form4.xml · derivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,957 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 16:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 7,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017630 · form4.xml · derivative · entry 3 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 16:52 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 905 | $27.19 | $24,606.95 |
DisclosureSEC source: 0001127602-22-017630 · form4.xml · nonDerivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,311 Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 16:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 7,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017630 · form4.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · balance_after: This amount is rounded down to the nearest whole share and excludes a previously reported 0.165 fractional share. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:35 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017240 · form4.xml · derivative · entry 6 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,591 Underlying: Ordinary Shares · 3,796 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 6/9/2022. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 6/9/2022. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:35 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 532 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017240 · form4.xml · derivative · entry 5 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 532 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:35 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 304 | $28.13 | $8,551.52 |
DisclosureSEC source: 0001127602-22-017240 · form4.xml · nonDerivative · entry 4 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,631.165 Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:35 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017240 · form4.xml · nonDerivative · entry 3 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,935.165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:35 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 43 | $28.13 | $1,209.59 |
DisclosureSEC source: 0001127602-22-017240 · form4.xml · nonDerivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,139.165 Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:35 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 532 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017240 · form4.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,182.165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 09, 2022 Filed May 10, 2022 18:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 80,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028162 · doc4.xml · derivative · entry 3 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,128 Underlying: Class A Common Stock · 80,128 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| May 08, 2022 Filed May 10, 2022 18:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 35,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028162 · doc4.xml · derivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 35,406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 5, 2021 the reporting person was granted 35,406 restricted stock units vesting on May 8, 2022. F2 · derivative.expiration_date: On May 5, 2021 the reporting person was granted 35,406 restricted stock units vesting on May 8, 2022. Read SEC document |
| May 08, 2022 Filed May 10, 2022 18:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 35,406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-028162 · doc4.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:48 UTC | Alkermes plc. ALKS · Entity 2392 | PurchaseOrdinary Shares | 1,650.165 | $30.22 | $49,860.40 |
DisclosureSEC source: 0001127602-21-024274 · form4.xml · nonDerivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650.165 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $30.21 to $30.2199. Full information regarding the number of shares purchased at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 16:17 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 7,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020032 · form4.xml · derivative · entry 2 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,585 Underlying: Ordinary Shares · 7,585 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/14/2022. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/14/2022. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 16:17 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 15,677 | $0.00 Strike: $24.72 | $0.00 |
DisclosureSEC source: 0001127602-21-020032 · form4.xml · derivative · entry 1 Alva Emily Peterson · CIK 0001738422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,677 Underlying: Ordinary Shares · 15,677 shares Expires 2031-06-14 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/14/2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.